KEY POINTS
  • Pfizer on Tuesday said final analysis of its antiviral Covid-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients.
  • Recent lab data suggests the drug retains its effectiveness against the fast-spreading omicron variant of the coronavirus.

In this article

Pfizer on Tuesday said final analysis of its antiviral Covid-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast-spreading omicron variant of the coronavirus.

The U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo based on interim results in around 1,200 people. The data disclosed on Tuesday includes an additional 1,000 people.

In this article